WallStSmart

Abbott Laboratories (ABT)vsTactile Systems Technology Inc (TCMD)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Abbott Laboratories generates 13352% more annual revenue ($44.33B vs $329.52M). ABT leads profitability with a 14.7% profit margin vs 5.8%. ABT appears more attractively valued with a PEG of 1.52. TCMD earns a higher WallStSmart Score of 58/100 (C).

ABT

Buy

51

out of 100

Grade: C-

Growth: 5.3Profit: 6.5Value: 7.3Quality: 4.8
Piotroski: 3/9

TCMD

Buy

58

out of 100

Grade: C

Growth: 8.0Profit: 6.0Value: 6.0Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ABTSignificantly Overvalued (-315.5%)

Margin of Safety

-315.5%

Fair Value

$25.23

Current Price

$104.83

$79.60 premium

UndervaluedFair: $25.23Overvalued
TCMDUndervalued (+3.7%)

Margin of Safety

+3.7%

Fair Value

$28.67

Current Price

$26.96

$1.71 discount

UndervaluedFair: $28.67Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ABT3 strengths · Avg: 8.3/10
Market CapQuality
$180.82B9/10

Large-cap with strong market position

Operating MarginProfitability
21.6%8/10

Strong operational efficiency at 21.6%

Free Cash FlowQuality
$2.63B8/10

Generating 2.6B in free cash flow

TCMD2 strengths · Avg: 8.0/10
Price/BookValuation
2.8x8/10

Reasonable price relative to book value

Revenue GrowthGrowth
21.0%8/10

Revenue surging 21.0% year-over-year

Areas to Watch

ABT4 concerns · Avg: 3.8/10
PEG RatioValuation
1.524/10

Expensive relative to growth rate

P/E RatioValuation
28.1x4/10

Moderate valuation

Revenue GrowthGrowth
4.4%4/10

4.4% revenue growth

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

TCMD4 concerns · Avg: 3.0/10
P/E RatioValuation
32.8x4/10

Premium valuation, high expectations priced in

Market CapQuality
$602.71M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
5.8%3/10

5.8% margin — thin

PEG RatioValuation
17.242/10

Expensive relative to growth rate

Comparative Analysis Report

WallStSmart Research

Bull Case : ABT

The strongest argument for ABT centers on Market Cap, Operating Margin, Free Cash Flow.

Bull Case : TCMD

The strongest argument for TCMD centers on Price/Book, Revenue Growth. Revenue growth of 21.0% demonstrates continued momentum.

Bear Case : ABT

The primary concerns for ABT are PEG Ratio, P/E Ratio, Revenue Growth.

Bear Case : TCMD

The primary concerns for TCMD are P/E Ratio, Market Cap, Profit Margin.

Key Dynamics to Monitor

ABT profiles as a value stock while TCMD is a growth play — different risk/reward profiles.

TCMD carries more volatility with a beta of 0.96 — expect wider price swings.

TCMD is growing revenue faster at 21.0% — sustainability is the question.

ABT generates stronger free cash flow (2.6B), providing more financial flexibility.

Bottom Line

TCMD scores higher overall (58/100 vs 51/100) and 21.0% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Abbott Laboratories

HEALTHCARE · MEDICAL DEVICES · USA

Abbott Laboratories is an American multinational medical devices and health care company with headquarters in Abbott Park, Illinois, United States. The company was founded by Chicago physician Wallace Calvin Abbott in 1888 to formulate known drugs; today, it sells medical devices, diagnostics, branded generic medicines and nutritional products. It split off its research-based pharmaceuticals business into AbbVie in 2013.

Visit Website →

Tactile Systems Technology Inc

HEALTHCARE · MEDICAL DEVICES · USA

Tactile Systems Technology, Inc., a medical technology company, is dedicated to the development and supply of medical devices for chronic diseases in the United States. The company is headquartered in Minneapolis, Minnesota.

Want to dig deeper into these stocks?